Details

Autor(en) / Beteiligte

• Martínez Martínez, Adela Leyre
• Calles Romero, Laura A
• Etxeberría Martín, Eider
• Monasterio Jiménez, Oihana
• Zabalegui Eguinoa, Alba
• Paja Fano, Miguel
• Monzón Mendiolea, Andoni
• Cadenas González, Aida
• Cabriada Nuno, José Luis
• Iglesias Hernández, Natalia Covadonga

Titel

Is there life after teduglutide?

Ist Teil von

• Nutrición hospitalaria : organo oficial de la Sociedad Española de Nutrición Parenteral y Enteral, 2020-07, Vol.34 (3), p.631-635

Ort / Verlag

Spain

Erscheinungsjahr

2020

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Intestinal failure (IF) is defined as a reduction in intestinal function below the minimum necessary for the absorption of nutrients, requiring intravenous supplementation to maintain health and/or growth. The most common cause is short bowel syndrome (SBS). Approximately 50% of patients with SBS have IF and require parenteral support. Teduglutide is a human glucagon-like peptide-2 analogue (GLP-2) approved for the treatment of patients with SBS. Clinical trial results have proven its efficacy by reducing volume and days of administration of parenteral nutrition and fluid therapy. Few publications evaluate the effects on long-term bowel function in respondent patients after teduglutide suspension. A patient with type I SBS (terminal jejunostomy) due to multiple surgeries for Crohn's disease, who was treated with liraglutide for one year and sequential teduglutide for 21 months, is described. With the former, a reduction in the need for contribution and debit by jejunostomy was observed. The GLP-2 analogue achieved a greater reduction in the hydric disbalance that allowed the suspension of the nocturnal suerotherapy, with weight gain and maintenance of nutritional parameters; situation maintained two years after its suspension.